Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.0920
+0.0070 (8.24%)
Aug 1, 2025, 10:28 AM AEST
H&E Equipment Services Revenue
Invex Therapeutics had revenue of 1.21M AUD in the twelve months ending December 31, 2024, up 9,856.93% year-over-year. In the fiscal year ending June 30, 2024, Invex Therapeutics had annual revenue of 1.21M with 164.06% growth.
Revenue
1.21M
Revenue Growth
+9,856.93%
P/S Ratio
5.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 1.21M | 753.17K | 164.06% |
| Jun 30, 2023 | 459.09K | 276.83K | 151.90% |
| Jun 30, 2022 | 182.25K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Ramsay Health Care | 17.12B |
| Telix Pharmaceuticals | 783.21M |
| Ansell | 3.00B |
| Mesoblast | 9.16M |